Superbugs: Exclusive Interviews Released with ABAC Therapeutics, Alchemy Biomedical and Oppilotech
SMi Reports: Expert insight into tackling the scientific, regulatory and economic challenges to combat antimicrobial resistance.
London, United Kingdom, November 24, 2017 --(PR.com)-- It is imperative for medical experts and drug discovery specialists to stay on top of the latest clinical advancements, developments and industry initiatives related to antimicrobial resistance. For this reason, SMi Group have gathered industry experts and government bodies to share their insights at the 20th annual conference on Superbugs and Superdrugs taking place on 19th and 20th March in London, UK.
SMi Group had the opportunity to sit down with three of the featured speakers to discuss some of the challenges they face in the industry and their strategies for overcoming them. The full interviews are available to read in the event download center at https://www.smi-online.co.uk/pharmaceuticals/uk/superbugs-superdrugs#tab_downloads.
"The fight against multi-resistant organisms requires the implementation of several measures coordinated at a global level. The rational use of antibiotics is an important challenge that we have to improve. Although, the biggest challenge is the discovery of new antibacterial agents with a novel mechanism of action, that allows us to increase the therapeutic arsenal against organisms that are practically lacking therapeutic alternatives," said Domingo Gargallo-Viola, Chief Scientific Officer from ABAC Therapeutics. "To discover new antibiotics, we have to be visionaries, we have to end with the unproductive nightmare of the last 50 years, for which we have to define new TPPs and improve the productivity of discovery processes, applying disruptive strategies to reduce the failure rate, and therefore the high technical risk associated with the area of infectious diseases."
When asked Oppilotech’s "cell envelope model," a novel platform being utilised to discover and develop an internal pipeline of new antibacterial drugs, John George, Founder and Chief Scientific Officer from Oppilotech said, "An accurate model allows us to identify nodes within the network which when inhibited, would weaken the outer membrane. The more permeable membrane would now allow compounds such as rifampin, erythromycin and kanamycin into the cell. This will impact AMR in a number of ways, firstly, it would allow these well established drugs to be used for the treatment of gram negatives. Secondly, because of the weakened membrane the intracellular concentration of drug would be much higher than normal, minimising the risk of low level resistance. Finally, the active agents could be given a lower dose which would reduce any associated toxicities."
On harnessing a patient's immune system to combat drug resistant bacteria, David Brown, Managing Director and Founder of Alchemy Biomedical Consulting said, "Our immune system is protecting us every second of the day from attack by infectious micro-organisms. It is immensely powerful, far more so than any antibiotic. So, I believe that immune modulation will be far more powerful in beating antibiotic resistance that just inventing more antibiotics or using combinations of antibiotics. Yet there is little research in this area. Bacteria invade by usurping our immune system. Research in the last few years has identified the mechanisms bacteria use to achieve this, but that knowledge has not been picked up by the antibiotic / microbiology community. I want to begin the process of getting it into the mainstream via this conference."
SMi’s 20th Annual conference on Superbugs & Superdrugs will take place on 19th & 20th March 2018 at the Copthorne Tara Hotel, Kensington in London, UK.
Further details including a full speaker line-up and detailed programme are available at www.superbugssuperdrugs.com/prcom
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.com.
SMi Group had the opportunity to sit down with three of the featured speakers to discuss some of the challenges they face in the industry and their strategies for overcoming them. The full interviews are available to read in the event download center at https://www.smi-online.co.uk/pharmaceuticals/uk/superbugs-superdrugs#tab_downloads.
"The fight against multi-resistant organisms requires the implementation of several measures coordinated at a global level. The rational use of antibiotics is an important challenge that we have to improve. Although, the biggest challenge is the discovery of new antibacterial agents with a novel mechanism of action, that allows us to increase the therapeutic arsenal against organisms that are practically lacking therapeutic alternatives," said Domingo Gargallo-Viola, Chief Scientific Officer from ABAC Therapeutics. "To discover new antibiotics, we have to be visionaries, we have to end with the unproductive nightmare of the last 50 years, for which we have to define new TPPs and improve the productivity of discovery processes, applying disruptive strategies to reduce the failure rate, and therefore the high technical risk associated with the area of infectious diseases."
When asked Oppilotech’s "cell envelope model," a novel platform being utilised to discover and develop an internal pipeline of new antibacterial drugs, John George, Founder and Chief Scientific Officer from Oppilotech said, "An accurate model allows us to identify nodes within the network which when inhibited, would weaken the outer membrane. The more permeable membrane would now allow compounds such as rifampin, erythromycin and kanamycin into the cell. This will impact AMR in a number of ways, firstly, it would allow these well established drugs to be used for the treatment of gram negatives. Secondly, because of the weakened membrane the intracellular concentration of drug would be much higher than normal, minimising the risk of low level resistance. Finally, the active agents could be given a lower dose which would reduce any associated toxicities."
On harnessing a patient's immune system to combat drug resistant bacteria, David Brown, Managing Director and Founder of Alchemy Biomedical Consulting said, "Our immune system is protecting us every second of the day from attack by infectious micro-organisms. It is immensely powerful, far more so than any antibiotic. So, I believe that immune modulation will be far more powerful in beating antibiotic resistance that just inventing more antibiotics or using combinations of antibiotics. Yet there is little research in this area. Bacteria invade by usurping our immune system. Research in the last few years has identified the mechanisms bacteria use to achieve this, but that knowledge has not been picked up by the antibiotic / microbiology community. I want to begin the process of getting it into the mainstream via this conference."
SMi’s 20th Annual conference on Superbugs & Superdrugs will take place on 19th & 20th March 2018 at the Copthorne Tara Hotel, Kensington in London, UK.
Further details including a full speaker line-up and detailed programme are available at www.superbugssuperdrugs.com/prcom
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.com.
Contact
SMi Group
Teri Arri
+44 (0) 20 7827 6162
http://www.superbugssuperdrugs.com/prcom
Teri Arri
+44 (0) 20 7827 6162
http://www.superbugssuperdrugs.com/prcom
Contact
Categories